A new radioligand therapy (RLT) manufacturing site is expected to come online by 2029 and strengthen the company’s specialized supply chain and manufacturing capabilities across its network of RLT production facilities.

Part of a larger, previously announced $23 billion company investment.

Two new manufacturing facilities will be built in North Carolina and Pennsylvania, the latter with a focus on next-generation cell therapy.

Part of a larger, previously announced $55 billion company investment

A new, next-generation active pharmaceutical ingredient (API) facility that will support the production of small molecule synthetic and peptide medicines, including an oral GLP-1. The project will bring “450 high-value jobs” to the area, including engineers, scientists, operations personnel and lab technicians, and 3,000 construction jobs.

Part of a larger, previously announced $27 billion company investment.

An expansion of the India-based company's existing Fall River facility. Will include an 83,000-square-foot addition to increase the company’s production capacity and operational efficiency.

Capital project investment over the next five years to strengthen the company’s manufacturing capabilities of plasma-derived therapies (PDTs) and help secure the U.S. medicine supply chain.

Expansion and modernization of the Lilly del Caribe manufacturing site to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. The project will generate an estimated 1,000 construction jobs and 100 additional high-tech manufacturing positions.

Part of a larger, previously announced $27 billion company investment.

A new site in Durham featuring two facilities dedicated to manufacturing biologics and sterile packaging. Also an expansion of an existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials.

A new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging.

These investments are expected to create 700 new jobs in North Carolina by 2030 and support more than 3,000 indirect jobs across the Novartis U.S. supply chain.

Part of a larger, previously announced $23 billion company investment.

Expansion of the company’s flagship biologics manufacturing facility in Frederick and the construction of a new state-of-the-art facility in Gaithersburg for the development of innovative molecules to be used in clinical trials.

The investment will support 2,600 jobs across the two sites, including the retention of local jobs, construction activity, and the creation of 300 highly skilled jobs.

Part of a larger, previously announced $50 billion company investment.